Webinar: Recent legislative developments affecting biologics and biosimilars
June 2019
Many of the top-selling drugs worldwide are biologics, and several companies are seeking to produce biosimilars to compete in these lucrative markets.
Recently, a flurry of proposed legislation has threatened to drastically alter the US regulation of and policies on wide ranging topics such as drug pricing, mandatory licensing, patent thickets, and the availability of post-grant proceedings.
Session 2 of our 2019 biosimilars webinars series focuses on key factors decision makers need to be aware of when considering currently pending legislation, including:
- Key provisions of proposed legislation.
- European perspectives and approaches to similar issues.
If you have any questions on this article or would like to propose a subject to be addressed by Synapse please contact us.
Latest topical issues
SPC manufacturing waiver for export and stockpiling comes into force 
Contributing authors
Matthew Royle, Evelyne Friedel, Judith Krens and external speakers: Heather M. Schneider , Michael W. Johnson and Tara L. Thieme (Willkie Farr & Gallagher LLP)